Synapse - Hematologic Malignancies, Division of

Search Within

Hematologic Malignancies, Division of

Results (13365)

Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly acute myeloid leukemia

Meeting Abstract

Iat, A.; Bewersdorf, J. P.; Gilhodes, J.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Bystrom, R. P.; Deangelo, D. J.; Berton, G.; more...
Blood (2024)

Fulltext@MSK | Save

Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase i study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies

Meeting Abstract

Richter, J.; Thomas, S. K.; Krishnan, A. Y.; Laubach, J. P.; Cohen, A. D.; Trudel, S.; Costa, L. J.; Bahlis, N. J.; Forsberg, P. A.; Kaedbey, R.; more...
Blood (2024)

Fulltext@MSK | Save

Superiority of post-transplant cyclophosphamide-based graft versus host disease (GvHD) prophylaxis in patients 70 years and older: A BMT CTN 1703 post-hoc analysis

Meeting Abstract

Abedin, S.; Lian, Q. H.; Martens, M. J.; Malki, M. M. A.; Elmariah, H.; Gooptu, M.; Larkin, K. T.; Shaffer, B. C.; Loren, A. W.; Solh, M. M.; more...
Blood (2024)

Fulltext@MSK | Save

Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)

Meeting Abstract

Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
Blood (2024)

Fulltext@MSK | Save

Increased inflammatory cytokines in plasma are associated with sustained treatment-free remission in chronic myeloid leukaemia

Meeting Abstract

Kok, C. H.; Saunders, V. A.; Shanmuganathan, N.; Liu, L.; Irani, Y. D.; Clarson, J.; Dang, P.; Yeung, D. T.; Yong, A. S. M.; Branford, S.; more...
Blood (2024)

Fulltext@MSK | Save

Systematic evaluation of GAPs and GEFs identifies ARHGAP45 as a targetable leukemia-specific dependency

Meeting Abstract

Zhang, P.; Cao, Z.; Pan, X.; Liu, Y.; Castro, C.; Kim, W. J.; Fujino, T.; Lewis, J.; Rahman, J.; Shahid, S.; more...
Blood (2024)

Fulltext@MSK | Save

Obecabtagene autoleucel (obe-cel) for adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Deep molecular remission may predict better outcomes

Meeting Abstract

Jabbour, E.; Park, J. H.; Shaughnessy, P.; Logan, A. C.; Sandhu, K. S.; Abedi, M.; Shah, B. D.; Bishop, M. R.; DeAngelo, D. J.; Lao-Sirieix, P.; more...
Blood (2024)

Fulltext@MSK | Save

Results from the first phase 1 clinical study of DR-01, a non-fucosylated anti-CD94 targeting antibody in patients with relapsed/refractory cytotoxic lymphomas: Dose escalation and optimization

Meeting Abstract

Zain, J.; Iyer, S. P.; Marchi, E.; Gandhi, M.; Kim, Y. H.; Khodadoust, M. S.; Brammer, J. E.; Poh, C.; Porcu, P.; Dilley, K.; more...
Blood (2024)

Fulltext@MSK | Save

Pre-apheresis prediction of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

Meeting Abstract

Rejeski, K.; Hansen, D. K.; Cordas Dos Santos, D. M.; De Menezes Silva Corraes, A.; Castaneda, O.; Dillard, C. M.; Alsdorf, W.; Frenking, J. H.; Purcarea, A.; Chhabra, S.; more...
Blood (2024)

Fulltext@MSK | Save

CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes

Meeting Abstract

Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
Blood (2024)

Fulltext@MSK | Save